MYC and cancer: Because the MYC oncoprotein is notoriously difficult to target, global inhibition of sumoylation with ML-792 (or with other similar drugs in the pipeline such as TAK-981) deserves attention as a potential therapy in MYC-driven cancers [194,201,202].